Phase II trial of gemcitabine/carboplatin (GC) followed by paclitaxel (P) in patients with performance status=2,3 or other significant co-morbidity (HIV infection or s/p organ transplantation) in advanced non-small cell lung cancer (NSCLC)

被引:0
|
作者
Bridges, B. B.
Thomas, L.
Hausner, P.
Doyle, L. A.
Bedor, M.
Smith, R.
Brahmer, J.
Edelman, M. J.
机构
[1] Univ Maryland, Baltimore, MD 21201 USA
[2] Johns Hopkins Med Inst, Baltimore, MD 21205 USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
7661
引用
收藏
页数:2
相关论文
共 50 条
  • [1] Phase II trial of gemcitabine/carboplatin followed by paclitaxel in patients with performance status=2.3 or other significant co-morbidity (HIV infection or s/p organ transplantation) in advanced non-small cell lung cancer
    Bridges, Benjamin B.
    Thomas, Leno
    Hausner, Petr F.
    Doyle, L. Austin
    Bedor, Michelle
    Smith, Ruth
    Brahmer, Julie
    Edelman, Martin J.
    [J]. LUNG CANCER, 2008, 61 (01) : 61 - 66
  • [2] Carboplatin plus gemcitabine followed by weekly paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC): A phase II study
    Tjan-Heijnen, V
    Timmer-Bonte, J
    van der Drift, M
    van Leeuwen, F
    de Boo, T
    Wagenaar, M
    van Die, L
    Bussink, J
    [J]. LUNG CANCER, 2005, 49 : S272 - S272
  • [3] A phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer
    Kelly, K
    Mikhaeel-Kamel, N
    Pan, ZX
    Murphy, J
    Prindiville, S
    Bunn, PA
    [J]. CLINICAL CANCER RESEARCH, 2000, 6 (09) : 3474 - 3479
  • [4] A phase II study of biweekly paclitaxel (P) and gemcitabine (G), followed by maintenance weekly paclitaxel in elderly patients with advanced non-small cell lung cancer (NSCLC)
    Pino, Maria Simona
    Gamucci, Teresa
    Mansueto, Giovanni
    Trapasso, Tiziana
    Narducci, Filornena
    Giampaolo, Maria Anna
    Fariello, Anna Maria
    Sperduti, Isabella
    Ceribelli, Anna
    Cognetti, Francesco
    [J]. LUNG CANCER, 2008, 60 (03) : 381 - 386
  • [5] A phase II trial of weekly paclitaxel and carboplatin for elderly patients with advanced non-small cell lung cancer (NSCLC).
    Usui, K
    Inoue, A
    Ishimoto, O
    Tanaka, M
    Koinumaru, S
    Matsubara, N
    Kanbe, M
    Gomi, K
    Saijo, Y
    Nukiwa, T
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 682S - 682S
  • [6] ECOG 1599: Randomized phase II study of paclitaxel/carboplatin or gemcitabine/cisplatin in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC).
    Tester, WJ
    Stephenson, P
    Langer, CJ
    Schiller, JH
    Johnson, DH
    Rapoport, BL
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 630S - 630S
  • [7] A phase II trial of induction therapy with gemcitabine and carboplatin followed by concurrent gemcitabine and radiotherapy in locally advanced non-small cell lung cancer (NSCLC)
    Thongprasert, S
    Sukthomya, V
    Charoentum, C
    Pojchamarnwiputh, S
    Saengsawang, P
    [J]. LUNG CANCER, 2005, 49 : S393 - S393
  • [8] Phase II trial with carboplatin/gemcitabine induction chemotherapy followed by radiotherapy concomitantly with paclitaxel/gemcitabine in stage III non-small cell lung cancer (NSCLC).
    Hirsh, V.
    Duclos, M.
    Souhami, L.
    Del Vecchio, P.
    Ofiara, L.
    Faria, S.
    Ayoub, J.
    Charpentier, D.
    Portelance, L.
    Soulieres, D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 398S - 398S
  • [9] Biweekly carboplatin and gemcitabine for untreated advanced non-small cell lung cancer (NSCLC). A multicenter phase II trial
    Domine, M
    Gomez, RG
    Firvida, J
    Delgado, J
    Estevez, L
    Docampo, LI
    Leon, A
    Pachon, V
    Casado, V
    Lobo, F
    [J]. LUNG CANCER, 2005, 49 : S242 - S242
  • [10] Paclitaxel and Carboplatin in combination with Gemcitabine (PCG): A phase I-II trial in non-small cell lung cancer (NSCLC)
    Favaretto, A
    Paccagnella, A
    Tumolo, S
    Barbieri, F
    Ceresoli, G
    Gulisano, M
    Oniga, F
    Bearz, A
    Fiorentino, MV
    [J]. ANNALS OF ONCOLOGY, 1998, 9 : 91 - 91